Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants.

British journal of clinical pharmacology·2026
Same author

Response to Letter to the Editor Regarding "The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants".

Clinical therapeutics·2026
Same author

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults.

British journal of clinical pharmacology·2026
Same author

2025 White Paper on Recent Issues in Bioanalysis: What is the Future of Bioanalytical LIMS? AI/ML Integration in Bioanalysis; Tear Sample Collection; Radiolabeled Mass Balance Studies; Chiral Assays; Bioanalysis of Antibody-Oligonucleotide & Bicycle Drug Conjugates (<u>PART 1A</u> - Recommendations on Mass Spectrometry Assays, Chromatography, Sample Preparation and Regulated Bioanalysis Sampling, Validating, Analyzing & Reporting <u>PART 1B</u> - Regulatory Agencies' Input on Regulated Bioanalysis/BMV).

Bioanalysis·2026
Same author

The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants.

Clinical therapeutics·2026
Same author

A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women.

Headache·2026

Related Experiment Video

Updated: May 11, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.9K

Patient-centric microsampling for abrocitinib pharmacokinetics: multiple-analytes assay bridging using Tasso device.

Sakambari Tripathy1, Katty X Wan2, Mohamed H Shahin1

  • 1Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA.

Bioanalysis
|September 5, 2024
PubMed
Summary

Tasso devices enable accurate measurement of abrocitinib and its metabolites from capillary blood. This microsampling method shows high concordance with traditional venous blood draws, supporting its use in pediatric studies.

Keywords:
Tasso+Tasso-SST®abrocitinib and its metabolitescapillary serumconcentration bridgingconcordancemicrosampling

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
00:05

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.2K
Microsampling in Targeted Mass Spectrometry-Based Protein Analysis of Low-Abundance Proteins
10:21

Microsampling in Targeted Mass Spectrometry-Based Protein Analysis of Low-Abundance Proteins

Published on: January 13, 2023

2.4K

Related Experiment Videos

Last Updated: May 11, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.9K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
00:05

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.2K
Microsampling in Targeted Mass Spectrometry-Based Protein Analysis of Low-Abundance Proteins
10:21

Microsampling in Targeted Mass Spectrometry-Based Protein Analysis of Low-Abundance Proteins

Published on: January 13, 2023

2.4K

Area of Science:

  • Pharmacokinetics
  • Analytical Chemistry
  • Clinical Diagnostics

Background:

  • Abrocitinib is an important medication requiring therapeutic drug monitoring.
  • Traditional venous blood sampling can be invasive and challenging, especially for pediatric populations.
  • Microsampling devices offer a less invasive alternative for collecting blood samples.

Purpose of the Study:

  • To evaluate the feasibility of using Tasso devices for capillary blood collection to measure abrocitinib and its metabolites.
  • To establish assay concordance between capillary and venous blood sampling methods.
  • To assess the suitability of Tasso devices for future pediatric studies involving abrocitinib.

Main Methods:

  • Capillary blood samples were collected using Tasso-SST® and Tasso+ devices.
  • Venous blood samples were collected for comparison.
  • Concentrations of abrocitinib and its metabolites (M1, M2, M4) were measured using validated assays for both sample types.
  • Assay concordance and pharmacokinetic parameter bioequivalence (AUC_last, C_max) were statistically evaluated.

Main Results:

  • High correlation coefficients (>0.98) were observed between capillary serum and venous plasma concentrations for all four analytes across three separate assays.
  • Pharmacokinetic parameters, including area under the curve (AUC_last) and maximum concentration (C_max), met bioequivalence criteria when comparing capillary and venous samples.
  • The Tasso devices demonstrated reliable performance in sample collection and analyte quantification.

Conclusions:

  • Tasso devices are feasible for collecting capillary blood samples for abrocitinib and metabolite analysis.
  • The assay concordance and bioequivalence between capillary and venous sampling support the use of Tasso devices.
  • Patient-centric microsampling with Tasso devices is a viable option for future abrocitinib pediatric studies.